[1]
Felsing, D.E.; Jain, M.K.; Allen, J.A. Advances in dopamine D1 receptor ligands for neurotherapeutics. Curr. Top. Med. Chem., 2019, 19(16), 1365-1380.
[2]
Wold, E.A.; Wild, C.T.; Cunningham, K.A.; Zhou, J. Targeting the 5-HT2C receptor in biological context and the current state of 5-HT2C receptor ligand development. Curr. Top. Med. Chem., 2019, 19(16), 1381-1398.
[3]
Liao, C.; de Molliens, M.P.; Schneebeli, S.T.; Brewer, M.; Song, G.; Chatenet, D.; Braas, K.M.; May, V.; Li, J. Targeting the PAC1 receptor for neurological and metabolic disorders. Curr. Top. Med. Chem., 2019, 19(16), 1399-1417.
[4]
Nguyen, T.; Thomas, B.F.; Zhang, Y. Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: Current approaches for therapeutics development. Curr. Top. Med. Chem., 2019, 19(16), 1418-1435.
[5]
Gupta, M.K.; Vasudevan, N.T. GPCRs and insulin receptor signaling in conversation: Novel avenues for drug discovery. Curr. Top. Med. Chem., 2019, 19(16), 1436-1444.
[6]
Li, J.; Hong, X.; Li, G.; Conti, P.S.; Zhang, X.; Chen, K. PET imaging of adenosine receptors in diseases. Curr. Top. Med. Chem., 2019, 19(16), 1445-1463.
[7]
He, P.; Zhou, W.; Liu, M.; Chen, Y. Recent advances of small molecular regulators targeting G protein-coupled receptors family for oncology immunotherapy. Curr. Top. Med. Chem., 2019, 19(16), 1464-1483.
